RXi Gains Exclusive License to Oral Delivery of RNAi Therapeutics Technology from University of Massachusetts
News Feb 11, 2009
RXi Pharmaceuticals Corporation has announced that it has licensed exclusive worldwide rights from the University of Massachusetts Medical School (UMMS) to certain technology for the oral delivery of RNAi therapeutics.
The technology was developed by Dr. Michael Czech, Professor and Chair, Program in Molecular Medicine at UMMS and an RXi founder, and Dr. Gary R. Ostroff, Professor of Molecular Medicine at UMMS and an RXi collaborator. Financial terms were not disclosed.
Going forward, management noted, RXi intends to work with pharmaceutical and biotechnology partners to advance the discovery and development of orally delivered rxRNA™ therapeutics for a host of inflammatory diseases.
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.
For centuries, gardeners have attempted to breed blue roses with no success. But now, thanks to modern biotechnology, the elusive blue rose may finally be attainable. Researchers have found a way to express pigment-producing enzymes from bacteria in the petals of a white rose, tinting the flowers blue.
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019
2nd World Congress on Genetics & Genetic Disorders
May 13 - May 14, 2019